Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies - Mita, M M; Mita, A C; Chu, Q S (J Clin Oncol, 2008)
et al.